KVUE
Kenvue Inc.
$19.05
장중 · Vol 1.23M · 52주 $14.02–$20.82 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $18.92 · Aug 31, 2026
KVUE 가격 추세
종가
$18.92
시가
$19.05
고가
$19.10
저가
$18.83
30초 브리핑
KVUE 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 74%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 15.2배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 0.9배
거래량은 최근 평균 범위입니다.
2026-11-05
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
KVUE 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
1 Kenvue Way · Summit, NJ, United States · 직원 21,780명
시가총액
$36.26B
Trailing P/E
22.2
최근 12개월 이익 기준
Forward P/E
15.2
이익 증가 기대 반영
EPS (TTM)
$0.84
배당 수익률
4.38%
배당성향
97.7%
지속 가능성 점검
베타
0.43
시장보다 방어적
ROE
15.6%
P/B
3.44
EV/EBITDA
12.7
52주 범위
$14.02 – $20.82
현재 위치 74%
거래량
11.01M
20일 평균 12.49M · 0.9배
애널리스트 의견
매수 14%
총 14명 · 0m
DITM LEAPS Analysis
KVUE 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KVUE280121C00013000 | 1/21/28 · 1.4Y | $13.00 | $6.42 | 2.6x | 0.8719 | 8.5% | 13.23% | 41.50% | 492 | 84.16 | |
| KVUE280121C00010000 | 1/21/28 · 1.4Y | $10.00 | $9.13 | 1.8x | 0.8866 | 2.7% | 35.62% | 81.01% | 373 | 75.48 | |
| KVUE271217C00015000 | 12/17/27 · 1.3Y | $15.00 | $4.65 | 3.3x | 0.8158 | 16.6% | 21.51% | 36.69% | 1,282 | 74.85 | |
| KVUE280121C00015000 | 1/21/28 · 1.4Y | $15.00 | $4.05 | 3.8x | 0.8158 | 4.2% | 56.79% | 36.16% | 806 | 70.47 | |
| KVUE280121C00017000 | 1/21/28 · 1.4Y | $17.00 | $2.83 | 5.1x | 0.7581 | 33.6% | 29.68% | 25.95% | 1,638 | 63.04 | |
| KVUE271217C00013000 | 12/17/27 · 1.3Y | $13.00 | $6.25 | 2.5x | 0.8254 | 5.9% | 72.00% | 72.12% | 230 | 58.45 |
재무제표
KVUE 연간 손익·현금흐름·재무상태
매출 성장률
-2.1%
최근 연간 YoY
EPS 성장률
+40.7%
최근 연간 YoY
영업이익률
18.0%
최근 연간
FCF 마진
11.4%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $15.12B-2.1% | $15.46B+0.1% | $15.44B+3.3% | $14.95B |
| 매출총이익 | $8.79B-1.9% | $8.96B+3.7% | $8.64B+4.3% | $8.29B |
| 영업이익 | $2.71B+3.3% | $2.63B+5.5% | $2.49B-7.3% | $2.69B |
| 순이익 | $1.47B+42.7% | $1.03B-38.1% | $1.66B-19.4% | $2.06B |
| 희석 EPS | $0.76+40.7% | $0.54-40.0% | $0.90-17.6% | $1.09 |
| EBITDA | $2.99B+21.0% | $2.47B-22.3% | $3.17B-3.2% | $3.28B |
| 영업현금흐름 | $2.20B+24.2% | $1.77B-44.2% | $3.17B+25.5% | $2.52B |
| 잉여현금흐름 | $1.72B+29.0% | $1.33B-50.5% | $2.70B+25.5% | $2.15B |
| 총자산 | $27.08B+5.8% | $25.60B-8.1% | $27.85B+2.0% | $27.32B |
| 총부채 | $8.67B-0.5% | $8.72B+3.5% | $8.43B+7164.7% | $116.00M |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
KVUE 실적·배당 일정
매출 하단
$3.81B
EPS 하단
$0.28
매출 상단
$3.90B
배당 지급일
2026-08-26
6일 전
실적 발표일
2026-11-05
D-65
EPS 상단
$0.32
매출 컨센서스
$3.86B
EPS 컨센서스
$0.29
배당락일
2026-08-12
20일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Aug 12, 2026 | $0.2100 |
| May 13, 2026 | $0.2080 |
| Feb 11, 2026 | $0.2080 |
| Nov 12, 2025 | $0.2080 |
| Aug 13, 2025 | $0.2080 |
| May 14, 2025 | $0.2050 |
| Feb 12, 2025 | $0.2050 |
| Nov 13, 2024 | $0.2050 |
뉴스
KVUE 관련 최신 기사
주주환원This Dividend King Just Offered a Buy-the-Dip Opportunity
Deal skepticism and litigation fears still weigh on this consumer staples stalwart.
Motley Fool · Aug 31, 2026
M&AKimberly Clark (KMB) Names New Legal Chief As Kenvue Deal Puts Valuation In Focus
Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...
Simply Wall St. · Aug 27, 2026
- 실적
Kimberly Clark (KMB) Stock Looks Below Fair Value While Earnings Lag
Kimberly-Clark stock has declined 11.1% over the past year, yet both its earnings multiples and a Discounted Cash Flow (DCF) intrinsic value estimate currently point to a cheaper valuation than the market price suggests. With the share price near US$110, the key issue for investors is whether this apparent discount fairly reflects the company’s cash generation and risk profile. The 11.1% share price decline over 1 year signals that investors have been cautious on Kimberly-Clark despite a...
Simply Wall St. · Aug 27, 2026
실적Estee Lauder Stock Jumped On A Bigger Margin Promise
The beauty group's repricing rests on a profit plan it controls, while the low end of its new sales guidance is no faster than the year just ended.
Trefis · Aug 24, 2026
실적Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings
Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...
Simply Wall St. · Aug 21, 2026
- 제품·기술
Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?
In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...
Simply Wall St. · Aug 20, 2026
일반Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future
Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.
Motley Fool · Aug 20, 2026
- 제품·기술
Will a Neutrogena boycott by Hayden Panettiere's fans work?
Panettiere's death has re-ignited calls to boycott Neutrogena, which she said ended a partnership after she spoke out about postpartum depression.
USA TODAY · Aug 20, 2026
- 제품·기술
Kenvue (KVUE) Launches Zyrtec Spray As Its Undervalued Case Faces A Fresh Test
Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...
Simply Wall St. · Aug 20, 2026
M&AJim Cramer Said Kimberly-Clark Corporation (NYSE:KMB) + Kenvue Could Take On P&G – But Is He Right?
Personal care products provider Kimberly-Clark Corporation (NYSE:KMB)’s shares are down by 17% over the past year and are up by 9% year-to-date. It is currently undergoing a major transformation through acquiring Kenvue. Cramer has discussed Kimberly-Clark Corporation (NYSE:KMB)’s acquisition several times and linked its performance with consumer goods giant Procter & Gamble. In his morning […]
Insider Monkey · Aug 14, 2026
홀더
KVUE 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
96.0%
기관 보유 (유동주식)
96.0%
내부자 보유
0.1%
기관 수
1,400
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| FMR, LLC | 157.05M | $2.97B | 8.2% | 16.3% | Jun 30, 2026 |
| Blackrock Inc. | 150.83M | $2.85B | 7.8% | 3.8% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 125.31M | $2.37B | 6.5% | 0.7% | Jun 30, 2026 |
| State Street Corporation | 121.62M | $2.30B | 6.3% | 1.7% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 93.30M | $1.76B | 4.9% | 0.9% | Jun 30, 2026 |
| Geode Capital Management, LLC | 52.02M | $982.16M | 2.7% | 1.5% | Jun 30, 2026 |
| Pentwater Capital Management Lp | 51.13M | $965.33M | 2.7% | -1.7% | Jun 30, 2026 |
| Independent Franchise Partners, LLP | 50.43M | $952.08M | 2.6% | 2.5% | Jun 30, 2026 |
| NORGES BANK | 46.16M | $871.44M | 2.4% | 5.2% | Jun 30, 2026 |
| Massachusetts Financial Services Co. | 44.72M | $844.23M | 2.3% | -10.1% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.
.png&w=3840&q=75)
.png&w=3840&q=75)
![[일간 리포트]제조업 부활과 연준 의장 지명이 불러온 시장 레짐 변화(2026.02.03)](/_next/image?url=%2Fuploads%2F1770078056935_unnamed_(22).png&w=3840&q=75)
![[일간 리포트]금 $5,000 돌파와 트럼프 관세 충격, 셧다운 위기(2026.01.27)](/_next/image?url=%2Fuploads%2F1769471747807_unnamed_(17).png&w=3840&q=75)